Can a genetic test pick the best chemo for triple negative breast cancer?

NCT ID NCT01982448

Completed Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two chemotherapy drugs, cisplatin and paclitaxel, given before surgery to 147 women with triple negative breast cancer. The goal was to see if a genetic test called HRD could predict which drug would work better. Researchers measured how much the tumor shrank after treatment to compare the drugs and the test's accuracy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cisplatin and paclitaxel (chemotherapy drugs)

What this could lead to

If successful, this could help doctors choose the best chemotherapy for each patient based on a genetic test, improving treatment outcomes for triple negative breast cancer.

What could go wrong

This is a phase II trial with only 147 participants, so results may not apply to all patients. The HRD test may not reliably predict response, and the study is already completed, meaning findings are preliminary.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University

Durham, North Carolina, 27710, United States
Indiana University- Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Johns Hopkins University

Baltimore, Maryland, 21287, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center-Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Cancer Center-Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Cancer Center-Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Cancer Center-Rockville Centre

Rockville Centre, New York, 11570, United States
Memorial Sloan Kettering Cancer Center-Sleepy Hollow

Sleepy Hollow, New York, 10591, United States
Memorial Sloan Kettering Cancer Center-West Harrison

Harrison, New York, 10604, United States
Seattle Cancer Alliance at EvergreenHealth

Kirkland, Washington, 98034, United States
South Shore Hospital

Weymouth, Massachusetts, 02190, United States
University of Alabama

Birmingham, Alabama, 35294, United States
University of North Carolina- Lineberger Cancer Center

Chapel Hill, North Carolina, 27599, United States
University of Washignton

Seattle, Washington, 98195, United States
Universtiy of Pittsburgh- Magee-Womens Hospital

Pittsburgh, Pennsylvania, 15213, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States